secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021212
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla Q1 net loss $27.5M; cash $192.7M funds operations into 2025
-------------------------------------------------------------------

- Cash and equivalents $192.7M as of March 31, 2023, down from $215.5M at Dec 31, 2022.
- Net loss $27.5M vs $24.3M in Q1 2022; R&D expense rose to $21.7M from $16.9M.
- Phase 2 potentially registrational BA3011 UPS study enrolling; LMS cohort readout expected 2H23.
- FDA meeting request for BA3011 NSCLC Phase 2 part 2 on track for 1H23; initiation in 2H23.
- BA3021 NSCLC interim readout and BA3071 Phase 1 data readout both on track for 2H23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017023021212/0000950170-23-021212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017023021212/bcab-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer